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Abstract
Background: Depression and anxiety may unfavorably impact on cardiac autonomic
dysregulation. However, it is unclear whether this relationship results from a causal
effect or may be attributable to confounding factors. We tested the relationship
between depression and anxiety with heart rate (HR) and heart rate variability
(HRV) across a 9‐year follow‐up (FU) period and investigated possible confounding by
antidepressant use and genetic pleiotropy.
Methods: Data (no. of observations = 6,994, 65% female) were obtained from the
longitudinal Netherlands Study of Depression and Anxiety, with repeated waves
of data collection of HR, HRV, depression, anxiety, and antidepressant use. Summary
statistics from meta‐analyses of genome‐wide association studies were used to
derive polygenic risk scores of depression, HR, and HRV.
Results: Across the 9‐year FU, generalized estimating equations analyses showed that
the relationship between cardiac autonomic dysregulation and depression/anxiety
rendered nonsignificant after adjusting for antidepressant use. A robust association was
found between antidepressant use (especially tricyclic antidepressants, selective serot
onin, and noradrenalin reuptake inhibitors) and unfavorable cardiac autonomic activity
across all waves. However, no evidence was found for a genetic correlation of depression
with HR and HRV, indicating that confounding by genetic pleiotropy is minimal.
Conclusions: Our results indicate that the association between depression/anxiety
and cardiac autonomic dysregulation does not result from a causal pathway or genetic
pleiotropy, and these traits might therefore not be inevitably linked. Previously reported
associations were likely confounded by the use of certain classes of antidepressants.
K E YWORD S
antidepressants, anxiety/anxiety disorders, depression, electrophysiology, gene‐environment,
genetics, stress
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1 | INTRODUCTION
Depressive and anxiety disorders have been found to be associated
with cardiac autonomic dysregulation, reflected by a significantly
higher heart rate (HR) and lower heart rate variability (HRV) than
healthy controls (Alvares, Quintana, & Hickie, 2016; Bleil, Gianaros,
Jennings, Flory, & Manuck, 2008; Carney, Freedland, & Veith, 2005;
Chalmers, Quintana, Abbott, & Kemp, 2014; Chang et al., 2012;
Chang et al., 2013; Hu et al., 2018; Kemp, Quintana, Felmingham,
Matthews, & Jelinek, 2012; Watkins, Grossman, Krishnan, & Sher-
wood, 1998; Yeh et al., 2016). This correlational finding has been
cited in support of two different hypotheses. In the first hypothesis,
cardiac autonomic dysregulation is thought to directly result from
depressive and anxiety disorders and to be part of the explanation
for the comorbidity of depression and anxiety with cardiovascular
disease (CVD) because poor cardiac autonomic regulation constitutes
a risk factor for CVD (Carney, Freedland, Miller, & Jaffe, 2002;
Palatini & Julius, 2004; Tsuji et al., 1996). According to this
hypothesis, psychological distress accompanying depressive and
anxious mood states leads to neuroendocrine or central autonomic
outflow alterations, affecting autonomic activity in the periphery
(Musselman, Evans, & Nemeroff, 1998). The second hypothesis
reverses the causal mechanism underlying the association. It sees
cardiac autonomic dysregulation, possibly occurring in the wake of
chronic stress, as a cause of allostatic adaptations in the brain and
neuroendocrine systems, which in turn lead to mental health
disorders (Jandackova, Britton, Malik, & Steptoe, 2016).
We voice concerns about both causal hypotheses based on three
grounds. First, close inspection of the results of various correlational
studies reveals them to be conflicting, as illustrated by findings of
Kemp et al. (2010), Kemp et al. (2012), and Kemp et al. (2014). In
2010, these authors conducted a meta‐analysis concluding that HRV
was reduced in patients with depression (Kemp et al., 2010), and in
2012 they conducted a case‐control study showing that the greatest
reduction in HRV was displayed in depressed participants with
comorbid generalized anxiety disorder (GAD; Kemp et al., 2012). A
large cohort study in 2014 reached the contradictory conclusion that
only GAD with small effect sizes and not depression or comorbid
depression and anxiety disorder were associated with decreased
HRV (Kemp et al., 2014). Other large studies have suggested a lack of
a direct relationship between anxiety and depression with cardiac
autonomic activity (Hu, Lamers, Penninx, & De Geus, 2017; Licht
et al., 2015; OʼRegan, Kenny, Cronin, Finucane, & Kearney, 2015).
One of the explanations for these inconsistent findings might be
incomplete control of confounding factors.
One particular confounding factor provides our second ground
for concern in interpreting the relationship of depression and anxiety
with cardiac autonomic activity as causal. Several studies, including
our own, have indicated that the relationship between cardiac
autonomic activity and mental health might be largely attributable to
antidepressant use (Davidson, Watkins, & Owens, 2005; Hu et al.,
2017; Licht, De Geus, van Dyck, & Penninx, 2010; Licht, Penninx, &
De Geus, 2012; Noordam et al., 2015; O’Regan et al., 2015; Udupa,
Thirthalli, & Sathyaprabha, 2011). The evidence for an impact of
antidepressant use on HR and HRV is much more robust than that for
depressive and anxiety disorders. Even so, ambiguity also remains in
this area. Most studies found large and robust associations between
the use of tricyclic antidepressants (TCAs) and cardiac autonomic
dysregulation (Alvares et al., 2016; Kemp et al., 2010; Tegegne, Man,
van Roon, Riese, & Snieder, 2018; Udupa et al., 2011; Van Zyl,
Hasegawa, & Nagata, 2008). However, findings concerning other
types of antidepressants are less consistent. For instance, selective
serotonin reuptake inhibitors (SSRIs) were sometimes found to have
no impact on HRV (Kemp et al., 2010; Udupa et al., 2011), a negative
impact on HRV (Kemp et al., 2016; Licht et al., 2010; O’Regan et al.,
2015), or a beneficial effect on HRV (Van Zyl et al., 2008) or HR
(Licht et al., 2010; Van Zyl et al., 2008).
A third concern about causal hypotheses on the relationship of
depression and anxiety with cardiac autonomic dysregulation is the
possibility of pleiotropic genetic effects. Overlapping genetic effects
may lead to an association between different biological systems that
independently affect different outcomes (e.g., emotion regulation by
the brain and cardiac regulation by the autonomic nervous system)
without the need for a direct causal effect of one on the other.
Previous studies have already demonstrated a significant genetic
contribution to both internalizing psychopathology like anxiety and
depression (Demirkan et al., 2011; Lubke et al., 2012; Sullivan, Neale,
& Kendler, 2000) as well as resting HR (Dalageorgou et al., 2008;
Russell, Law, Sholinsky, & Fabsitz, 1998) and HRV (De Geus, Van
Lien, Neijts, & Willemsen, 1996) Furthermore, for many complex
traits genetic pleiotropy appears to be quite common (Pickrell et al.,
2016).
In short, it remains to be established whether previously found
relationships between depression/anxiety and cardiac autonomic
activity result from a causal effect in one or both directions, and/or
may be attributable to confounding factors. Adjudicating between
the above possibilities is important, as it would lead to important
information for treatment strategies. For instance, if depression/
anxiety directly causes cardiac autonomic dysregulation, prevention
and early treatment of poor mental health might intervene in the
chain of causation toward cardiac morbidity and mortality. However,
if antidepressants account for the relationship between depression/
anxiety and cardiac autonomic dysregulation, clinicians should exert
extra caution in prescribing these, and other therapy options should
be explored that render less adverse side effects. Alternatively, if
shared genetic effects underlie this relationship, poor mental health
and cardiac autonomic dysregulation should be treated indepen-
dently, as neither causes the other.
In the present study, we used genotype and phenotype data from
the large longitudinal cohort of the Netherlands Study of Depression
and Anxiety (NESDA; no. of observations = 6,994), one of the largest
and longest follow‐up (FU) studies allowing to examine the relation-
ship of depressive and anxiety disorders and antidepressant use with
cardiac autonomic activity. These data were combined with results
from large genome‐wide association studies (GWAS) to compute
polygenic risk scores (PRS) for depression (Ripke et al., 2013), resting
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HR (Den Hoed et al., 2013), and the root mean square of differences
between successive interbeat intervals (RMSSD, a frequently used
measure of HRV; Nolte et al., 2017).
Based on these data we investigated whether (a) depression/
anxiety was associated with cardiac autonomic activity across four
waves of assessment during a 9‐year FU period, (b) the use of three
classes of antidepressants (TCAs, SSRIs, and selective serotonin and
noradrenalin reuptake inhibitors [SNRIs]) was associated with cardiac
autonomic activity, (c) depression/anxiety was associated with
cardiac autonomic activity, independently from this effect of
antidepressant use, and (d) a genetic correlation exists between
depression/anxiety and cardiac autonomic activity indicating poten-
tial genetic confounding. As we expected antidepressants to impact
on cardiac autonomic activity, we additionally investigated whether
(e) a genetic vulnerability for cardiac autonomic activity might
enhance the effect of antidepressant use on cardiac autonomic
dysregulation. Such pharmacogenetic moderation might explain the
discrepant findings in the literature regarding the use of some types
of antidepressants, such as SSRIs. Moreover, knowledge about such a
moderation effect would be clinically relevant as mental health
practitioners would be advised against prescribing antidepressants
especially to patients with a genetic vulnerability for cardiac
autonomic dysregulation.
2 | MATERIALS AND METHODS
2.1 | Subjects
Subjects were participants in NESDA, a cohort study examining the
long‐term course of depression and anxiety, including 2,981
participants aged 18–65 years recruited from the community,
primary care, and mental health care in the Netherlands. The NESDA
sample consists of persons with a current diagnosis of depression
and/or anxiety disorder, a prior history of these disorders, and
healthy controls. A 4‐hr baseline measurement was conducted
between September 2004 and February 2007, and FU assessments
took place after 2, 4, 6, 8, and 9 years. A detailed description of the
rationale, objectives, and methods of the NESDA study can be found
elsewhere (Penninx et al., 2008). The study protocol was approved by
the ethical review board of each participating center and written
informed consent was provided by all participants. The study was
performed in compliance with the declaration of Helsinki.
Data for the present study were drawn from baseline (n = 2,981),
2‐year (n = 2,596), 6‐year (n = 2,256), and 9‐year (n = 2,069) FU.
Subjects were included if they had genetic and cardiac autonomic
data. This resulted in a total of 2,319 subjects at baseline, 1,870
subjects at 2‐year FU, 1,543 subjects at 6‐year FU, and 1,262
subjects at 9‐year FU (Figure 1). Missing genetic data were mostly
due to refusal to partake in DNA sampling with a smaller part lost to
genotyping errors. Missing physiological data at each wave was due
to the interview being held by telephone or at‐home interviews
without ANS recording, equipment failure during the assessment, or
poor electrocardiogram (ECG) quality.
2.2 | Depressive/anxiety disorder
Participants were considered to have a current depressive and/or
anxiety disorder if they had in the 6‐month preceding the assessment
a diagnosis of major depressive disorder and/or anxiety disorder
(panic disorder, social phobia, and/or GAD) according to the DSM‐IV‐
based Composite International Diagnostic Interview, version 2.1
(Wittchen, 1994).
Number of participants at 
baseline data collection 
n=2981
No genotype data n=407
No autonomic data n=255
Number of participants at 
2-year FU data collection 
n=2596
Number of participants at 
6-year FU data collection 
n=2256
Number of participants at 
9-year FU data collection 
n=2069
Number of participants 
included for study
n=2319
Number of participants 
included for study
n=1870
Number of participants 
included for study
n=1543
Number of participants 
included for study
n=1262
No genotype data n=337
No autonomic data n=389
No genotype data n=291
No autonomic data n=422
No genotype data n=269
No autonomic data n=538
F IGURE 1 NESDA wave flow diagram. FU, follow‐up; NESDA, Netherlands Study of Depression and Anxiety
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2.3 | Antidepressant use
Participants were requested to bring their medication containers to
the assessments so that medication use could be determined.
Persons were considered to be using antidepressants if they reported
to have used medication frequently (daily or more than 50% of the
time) in the past month. We established the use of TCAs (ATC code
N06AA), SNRIs (ATC code N06AX), and SSRIs (ATC code N06AB).
2.4 | Physiological measurements
Physiological data were recorded with the “Vrije Universiteit
Ambulatory Monitoring System” (VU‐AMS), an unobtrusive portable
device. This device contains a six‐electrode configuration that
measures ECGs and changes in thorax impedance (ICG; De Geus &
Van Doornen, 1996). Data cleaning was performed with VU‐AMS
software (version 4.0; VU University Amsterdam, www.vu‐ams.nl).
Movement registration through vertical accelerometry was used to
remove periods where the subjects were not stationary. Bad ECG
signal fragments (artifacts) were automatically detected, after which
a modified version of the algorithm by Christov (Christov, 2004) was
used to detect R‐wave peaks. Visual data cleaning assured that
suspicious interbeat interval (IBIs) and breathing cycles were
corrected or discarded when displaying irregularities.
HR and RMSSD were directly derived from the IBI time series
from the ECG signal (De Geus & Van Doornen, 1996). Respiratory
sinus arrhythmia (RSA), another frequently used measure of HRV,
combined ECG with the respiration signal obtained from ICG, and
was obtained by subtracting the shortest IBI during HR acceleration
at inspiration from the longest IBI during HR deceleration at
expiration for all breaths (De Geus, Willemsen, Klaver, & Van
Doornen, 1995). An event marker was used to divide the assessment
into different conditions. At each wave, an average score of HR,
RMSSD, and RSA was made by combining the conditions that were
present at all waves: a supine rest condition with blood pressure
measurement (±11min) and three sitting conditions: a psychiatric
interview (±42min), a general interview (±36min), and a computer
task (±12min), resulting in an average total recording duration of
±107min.
2.5 | GWAS data and PRSs
GWAS data for HR and RMSSD were derived from Den Hoed et al.
(2013), n = 85,787 and Nolte et al. (2017), n = 26,78, respectively.
GWAS data for the major depressive disorder were derived from the
GWAS summary statistics publicly released by the Psychiatric GWAS
Consortium, excluding the dataset from 23andMe (n = 173,005;
Ripke et al., 2013). PRSs for depression, HR, and RMSSD were based
on the GWAS summary statistics (supplementary methods). As the
genetic correlation between depression and anxiety has been shown
to be very high (rg = 0.80; Wray et al., 2018), we have performed the
analyses only with the depression‐PRS under the assumption that the
results would be very similar for the anxiety‐PRS.
2.6 | Statistical analyses
Data were analyzed using SPSS, version 22.0. Missing data were
handled via full information maximum likelihood. RMSSD and RSA
values were highly skewed and therefore ln‐transformed for
analyses. All PRSs were standardized (mean of 0 and standard
deviation [SD] of 1) to aid the interpretability of the results.
Generalized estimating equations (GEE) analyses were performed
with an independent correlation structure to take into account within‐
person correlations due to multiple observations per participant. GEE
analyses were used to test the validity of HR/RMSSD‐PRS and
depression‐PRS in predicting cardiac autonomic variables and depres-
sion, respectively within the NESDA sample. GEE analyses were also
used to investigate whether current depression/anxiety and the use of
antidepressants were associated with cardiac autonomic activity across
all waves within the NESDA sample. To investigate the consistency of
these relationships across waves, wave‐interaction terms were added to
the model. In the case of a consistent relationship, the interaction terms
are expected to equal zero. Pharmacogenetic moderation was
investigated by adding HR/RMSSD‐PRS‐by‐antidepressant interaction
terms to the model. Given our sample, power simulations carried out in
the R “MASS” package showed that we had sufficient power (80%) to
detect a pharmacogenetics moderation effect of R2 = 0.12 at α = .01
(supplementary methods). Correction for multiple testing was based on
Matrix Spectral Decomposition suggested by Nyholt (2004), which
corrects the α level, taking into account the correlations among the
predictors (HR‐PRS, RMSSD‐PRS, current depression/anxiety, TCA use,
SNRI use, and SSRI use). Accordingly, the criterion for statistical
significance was set at α = .0084.
To test for genetic pleiotropy, we used PRS and GWAS summary‐
level data to establish whether there was a genetic correlation of
depression/anxiety with cardiac autonomic activity. Two types of
analyses were performed. First, LD score regression (LDSC) analyses
were performed on GWAS summary level data of depression and the
cardiac autonomic traits to estimate their genetic covariance
captured by all genotyped single‐nucleotide polymorphism (SNPs;
Bulik‐Sullivan et al., 2015). Second, regression analyses established
whether HR‐PRS or RMSSD‐PRS were associated with depression
and anxiety and whether depression‐PRS was associated with the
cardiac autonomic variables.
All analyses were adjusted for sex, age, and wave. Analyses with
PRS were also adjusted for three ancestry‐informative principal
components, and interaction analyses were additionally adjusted for
covariate‐by‐gene and covariate‐by‐exposure interaction terms, as
suggested by Keller (2014).
3 | RESULTS
Table 1 shows the characteristics of our sample at baseline
(n = 2,319), 2‐year FU (n = 1,870), 6‐year FU (n = 1,543), and 9‐year
FU (n = 1,262). For instance, at baseline, our sample had a mean age
of 42.4 years (SD = 13.0) and included 66.1% females.
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3.1 | The association of depression/anxiety and
antidepressant use with cardiac autonomic activity
Table 2 shows the results of the GEE analyses establishing the
relationship of depression/anxiety and antidepressant use with the
cardiac autonomic activity. Without adjustment for antidepressant
use, depression/anxiety was not significantly associated with HR
(B = −0.228; p = .50), but (marginally) significantly associated with
RMSSD (B = −0.047; p = .011) and RSA (B = −0.052; p = .001) across
waves. However, after adjustment for antidepressant use, all
associations between depression/anxiety and cardiac autonomic
variables rendered nonsignificantly. In addition, no significant wave‐
interaction effects were found, suggesting that the associations did
not differ across waves (not tabulated).
TCA (B = 10.292; p < .001) and SNRI (B = 3.171; p < .001) use were
associated with a significantly higher HR, while SSRI use was
associated with a lower HR (B = −1.134; p = .006) across waves. Use
of all antidepressants was associated with lower RMSSD and RSA,
with the largest effect of TCA (RMSSD: B = −0.651; p < .001; RSA:
B = −0.652; p < .001), followed by SNRI (RMSSD: B = −0.312; p < .001;
RSA: B = −0.307; p < .001) and SSRI (RMSSD: B = −0.134; p < .001,
RSA: B = −0.150; p < .001). No significant wave‐interaction effects
were found, suggesting that the associations were consistent across
waves (not tabulated).
3.2 | The genetic association of depression/anxiety
with cardiac autonomic activity
First, we tested the validity of HR/RMSSD‐PRS in predicting
cardiac autonomic variables within NESDA, and the validity of the
depression‐PRS in predicting depression diagnosis within NESDA.
Figure S1 shows the explained variances in cardiac autonomic traits
by HR‐PRS and RMSSD‐PRS per wave for the various PRS
constructed in different ways. These findings support the consistency
of the contribution of polygenetic risk factors to variance in cardiac
autonomic activity across 9‐year FU data. We pursued the analyses
with the best performing PRS for HR and RMSSD (i.e., LDpred [0.03],
which assumes that 3% of all variants are causal for the trait of
interest). As expected, GEE analyses showed that HR‐PRS was
positively associated with HR (B = 1.810; p < .001), and negatively
associated with RMSSD (B = −0.067; p < .001) and RSA (B = −0.046;
p < .001) across all waves in NESDA. Also in line with expectations,
RMSSD‐PRS was negatively associated with HR (B = −0.755;
p < .001), and positively associated with RMSSD (B = 0.061;
p < .001) and RSA (B = 0.049; p < .001) across all waves (Table 2). In
addition, depression‐PRS was significantly associated with depres-
sion diagnosis across all waves (B = 0.186; p < .001; Figure S2).
After confirming the validity of HR/RMSSD‐PRS and depression‐
PRS, we investigated the genetic correlation between depression/
anxiety and cardiac autonomic activity. LDSC analyses using GWAS
summary statistics yielded small and statistically nonsignificant
genetic correlation estimates of depression with HR (rg = 0.08;
p = .062) and RMSSD (rg = 0.0755; p = .29). Congruently, we found
no associations of HR‐PRS (B = 0.017; p = .53) and RMSSD‐PRS
(B = 0.005; p = .84) with depression/anxiety in the NESDA dataset
(Figure S3). We also found depression‐PRS not to be associated
with HR (B = 0.301; p = .092), RMSSD (B = −0.015; p = .14), or RSA
(B = −0.014; p = .094). As these relationships might be affected
by antidepressant use, we reran the analyses with additional
TABLE 1 Sample characteristics
Wave
Baseline (n = 2319) 2‐Year FU (n = 1870) 6‐Year FU (n = 1543) 9‐Year FU (n = 1262)
Sociodemographic
Age, years (mean ± SD) 42.4 ± 13.0 44.6 ± 13.1 48.6 ± 13.0 51.2 ± 13.1
Female (%) 66.1 65.9 65.3 63.5
Mental health
Current depression/anxiety (%) 82.1 38.3 28.3 27.6
Depression (%) 47.7 59.5 57.4 54.6
Generalized anxiety disorder (%) 7.4 20.5 20.0 8.4
Social phobia (%) 29.1 37.5 29.7 32.4
Panic disorder (%) 11.6 30.5 28.8 17.3
IDS‐SR score (mean ± SD) 24.9 ± 13.3 25.0 ± 12.1 26.2 ± 12.3 25.1 ± 12.4
BAI score (mean ± SD) 13.9 ± 10.5 14.4 ± 9.6 14.8 ± 10.7 14.3 ± 9.8
Antidepressant use (%)
Use of TCA 2.8 3.0 3.3 4.0
Use of SNRI 4.4 4.4 4.0 4.0
Use of SSRI 17.6 15.1 12.5 12.4
Cardiac autonomic variables
HR, beat/min (mean ± SD) 71.9 ± 9.6 72.7 ± 9.7 71.6 ± 9.6 70.7 ± 9.8
RMSSD, ms (median [IQR]) 31.6 (22.3–45.5) 30.0 (20.5–43.9) 22.2 (15.7–32.1) 27.0 (19.0–38.6)
RSA, ms (median [IQR]) 38.0 (26.5–53.9) 36.6 (24.9–52.3) 38.9 (26.4–55.6) 44.6 (31.6–62.0)
Abbreviations: BAI, beck anxiety inventory; FU, follow‐up; HR, heart rate; IDS‐SR, inventory of depressive symptomatology‐self report; IQR, interquartile
range; RMSSD, root mean square of differences between successive interbeat intervals; RSA, respiratory sinus arrhythmia; SD, standard deviation; SNRI,
selective serotonergic and noradrenergic reuptake inhibitors; SSRI, selective serotonin reuptake inhibitors; TCA, tricyclic antidepressant.
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adjustment for use of TCA, SNRI, and SSRI, but the results remained
insignificant. The LDSC and PRS analyses suggest that genetic
pleiotropic effects do not, or only very weakly, explain the relation-
ship between these traits.
3.3 | Pharmacogenetic moderation
The interaction terms testing pharmacogenetic moderation of
the HR/RMSSD‐PRS effect on the relationship between antidepressant
use and cardiac autonomic variables were all nonsignificant.
3.4 | Posthoc analyses with depression/anxiety
severity scores and antidepressant derived daily dose
To check for possible dose–response relationships of depression/
anxiety and antidepressant use with cardiac autonomic activity,
we reran the GEE analyses with depression/anxiety severity
scores and antidepressant derived daily dose (DDD; Table S1).
Similar to the results regarding depression/anxiety diagnosis,
all associations between depression/anxiety severity and cardiac
autonomic variables rendered nonsignificant after adjustment
for antidepressant use. Higher TCA DDD was significantly
associated with higher HR (B = 2.218; p = .007), lower RMSSD
(B = −0.249; p < .001), and RSA (B = −0.195; p < .001). In addition,
higher SNRI DDD was significantly associated with lower RMSSD
(B = −0.101; p < .001), and higher SSRI DDD was significantly
associated with lower RMSSD (B = −0.067; p < .001) and RSA
(B = −0.060; p = .001).
3.5 | Posthoc analyses using IBI‐adjusted HRV
variables
Because the ability of RMSSD and RSA to index cardiac autonomic
activity may be associated with the prevailing HR, we reran the GEE
analyses with IBI, and HRV variables corrected for the mean IBI (the
reciprocal of HR) as suggested by De Geus, Gianaros, Brindle,
Jennings, and Berntson (2019; Table S2). Overall, these results were
similar to the original GEE analyses, suggesting that the present
findings were not merely due to individual differences in HR.
4 | DISCUSSION
It is unclear whether the previously found relationship of depressive and
anxiety disorders with cardiac autonomic activity results from a causal
effect in either direction or may be attributable to confounding factors.
We investigated possible confounding by genetic pleiotropic effects in the
relationship between depression and anxiety and cardiac autonomic
activity but did not find evidence for this. The current study indicates that
the above relationship does not result from a causal pathway or genetic
pleiotropy, but is driven by the use of antidepressants. The use of TCAs,
SNRIs, and SSRIs was consistently associated with cardiac autonomic
dysregulation across the 9‐year FU.




B p R2 B p R2 B p R2
Main effects
HR‐PRS 1.810 <.001 .063 −0.067 <.001 .129 −0.046 <.001 .284
RMSSD‐PRS −0.755 <.001 .033 0.061 <.001 .125 0.049 <.001 .284
Current depression/anxiety −0.228 .50 .028 −0.047 .011 .119 −0.052 .001 .280
Current depression/anxiety −0.593 .070 .068 0.010 .58 .169 0.007 .67 .333
TCA use 10.292 <.001 −0.651 <.001 −0.652 <.001
SNRI use 3.171 <.001 −0.312 <.001 −0.307 <.001
SSRI use −1.134 .006 −0.134 <.001 −0.150 <.001
Pharmacogenetic moderation
HR‐PRS*TCA use 1.086 .31 .108 −0.104 .070 .188 −0.085 .10 .344
HR‐PRS*SNRI use 0.809 .17 0.008 .84 0.033 .34
HR‐PRS*SSRI use 0.310 .40 −0.011 .61 −0.013 .50
RMSSD‐PRS*TCA use 2.281 .029 .079 0.070 .20 .185 0.045 .37 .345
RMSSD‐PRS*SNRI use 0.176 .81 −0.048 .17 −0.063 .054
RMSSD‐PRS*SSRI use 0.488 .26 −0.005 .83 −0.003 .87
Note: GEE analyses were adjusted for sex, age, and wave. Analyses with PRS were also adjusted for ancestry‐informative principal components. Analyses
with PRS‐interaction terms were additionally adjusted for covariate‐by‐gene and covariate‐by‐exposure interaction terms. R2 values are based on
regression analyses. Boldface indicates statistical significance (p < .0084).
Abbreviations: HR, heart rate; PRS, polygenic risk scores; RMSSD, root mean square of differences between successive interbeat intervals; RSA,
respiratory sinus arrhythmia; SNRI, selective serotonergic and noradrenergic reuptake inhibitors; SSRI, selective serotonin reuptake inhibitors; TCA,
tricyclic antidepressant.
*interaction term
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Previous NESDA studies indicated that there was little evidence
for a direct association of depression and anxiety with cardiac
autonomic dysregulation (Hu et al., 2017; Licht et al., 2010). This was
confirmed by the current 9‐year FU study. In addition, no genetic
correlation between these domains was found: LDSC analyses
showed no significant association between GWAS summary level
data of depression and cardiac autonomic activity. In keeping, neither
HR‐PRS nor RMSSD‐PRS predicted diagnosed depression and
anxiety, and the depression‐PRS did not predict these cardiac
autonomic variables. The finding that a genetic correlation is lacking
between these traits is relevant, as this suggests that depression and
anxiety are not inevitably linked with cardiac autonomic dysregula-
tion, but that interventions are possible to break this deleterious
relationship.
The NESDA results align with other large cohort studies
showing that depression and anxiety may not directly cause
cardiac autonomic dysregulation, but these effects are, at large or
fully, attributable to the use of antidepressants (Noordam et al.,
2015; O’Regan et al., 2015; Tegegne et al., 2018). We found the
use of antidepressants to be consistently associated with cardiac
autonomic activity across 9‐year longitudinal data. In line with our
previous studies across shorter time spans (Hu et al., 2017; Licht
et al., 2010; Licht et al., 2012), we found a detrimental effect on
the cardiac autonomic activity of TCA use, followed by SNRI and
SSRI use. SSRI use might even have a slightly beneficial effect on
HR. Additional analyses with antidepressant DDD indicated that
there might be a dose–response effect of the use of TCAs, SNRIs,
and SSRIs on cardiac autonomic dysregulation. Although these
effects are robustly found within the literature, not all studies
agree on the effects of certain types of antidepressants, especially
SSRIs. We, therefore, hypothesized that the association between
antidepressant use and cardiac autonomic dysregulation might be
affected by pharmacogenetic moderation. However, we did not
find a moderation effect of genetic risk for high HR or low HRV,
meaning that the effects of antidepressant use were not amplified
by the genetic vulnerability, or ameliorated by genetic resilience.
Nonetheless, this study adds to the increasing evidence that
almost all antidepressants affect cardiac autonomic activity (Kemp
et al., 2014; O’Regan et al., 2015), with the strongest detrimental
effects associated with TCAs, and the mildest effects with SSRIs.
These results are in correspondence with recent findings in a very
large general population sample (n = 149,205), where similar
effects on HRV were found for TCAs, SNRIs, and SSRIs (Tegegne
et al., 2018). Although the relevant mechanisms are not entirely
understood, it is thought that antidepressants influence relay
nuclei of the parasympathetic nervous system in the brain stem
(Raul, 2003), inhibit cardiac vagal tone by exerting anticholinergic
activity (Lavretsky, Lesser, Wohl, & Miller, 1998), and/or inhibit
the reuptake of norepinephrine in the heart (Esler, Hasking,
Willett, Leonard, & Jennings, 1985). In addition, the electrophy-
siological effects that antidepressants exert on ion channels (e.g.,
the blockage of sodium and/or potassium channels) may affect the
cardiac action potential, thereby causing prolongation of the QT
interval and other cardiovascular side effects (Nachimuthu, Assar,
& Schussler, 2012; Sala et al., 2000). For instance, TCAs are
thought to affect a broad range of receptor pathways, including a
significant inhibition of central cholinergic neurotransmission,
impaired neuronal uptake of norepinephrine, and the blockage of
sodium channel conductance. Likewise, SNRIs are suggested to
stimulate cardiac sympathetic activity by increasing peripheral
norepinephrine concentrations and blocking cardiac sodium
channel conductance (Waring, 2012).
The major strength of this study is that it is one of the largest
studies with the longest FU to investigate the relationship of
diagnosed depression and anxiety and different classes of
antidepressants with cardiac autonomic activity, and the first to
address the role of genetics. A general limitation of the use of the
PRS is the limited amount of complex trait variance explained. In
the present analyses, PRS for autonomic traits captured 0.4–4.2%
of the related trait variance. The explanatory power of PRS is a
function of the discovery GWAS sample size: a larger training
dataset allows smaller sampling variance on the individual SNP
effect estimates, leading to a more powerful PRS. For our study,
we used the largest GWAS available up to date. In the future, PRS
derived from larger GWAS could be used to further confirm the
present findings. The question of adequate power is particularly
relevant with regard to the pharmacogenetic moderation analyses.
Our sample (no. of observations = 6,994) had sufficient power
(80%) to detect a gene‐by‐antidepressant interaction effect of
R2 = 0.12 for antidepressant use at α = .01. Therefore, our analyses
cannot exclude interaction effects smaller than these. However, an
effect of smaller size might not be of clinical relevance and
probably could not explain the discrepant findings in this research
area. Another limitation is that the used discovery (and target)
sample mainly includes individuals of European descent. This
lack of ancestral diversity limits the generalizability of our
findings. This study focused on diagnosed depression/anxiety and
symptom severity. However, the association of specific symptoms
or symptom clusters of depression and anxiety on autonomic
dysregulation cannot be ruled out by our findings. In addition, we
have not investigated the effect of the course of depression/
anxiety, such as chronicity, on cardiac autonomic activity. How-
ever, previous NESDA research over 6 years has shown that
neither chronic depression/anxiety nor onset or remission of
depression/anxiety was associated with the change in cardiac
autonomic functioning (Hu et al., 2017). Therefore, we do not
expect disease course to influence our findings. Lastly, although
the found association between antidepressant DDD and cardiac
autonomic dysregulation suggests a dose–response effect, the
current study did not include many participants who used
antidepressants in high dosage (DDD was equal or less than 1.5
for over 95% of the persons using antidepressants). Future
studies might further explore the effects of antidepressant dosage,
course of the disease, as well as different depressive and anxious
symptom dimensions on cardiac autonomic activity. This study
is unique in addressing the role of genetic pleiotropy and
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pharmacogenetic moderation in the relationship between depres-
sion, anxiety, antidepressant use, and cardiac autonomic dysregu-
lation across four waves in 9 years. This strength also means
that future replication studies in independent samples are
needed to verify or falsify the current findings regarding genetic
correlation and moderation.
5 | CONCLUSION
To conclude, in this large longitudinal dataset, we found no
evidence for a causal relationship between depressive and anxiety
disorders with cardiac autonomic activity. We found robust effects
of antidepressant use, with the strongest detrimental effect of
TCAs, followed by SNRIs and SSRIs. These results suggest that
previously reported associations of depression and anxiety with
cardiac autonomic dysregulation are likely caused by the con-
founding of antidepressant use. The finding that it is not genetic
pleiotropy, but rather antidepressant use that confounds the
relationship of depression and anxiety with cardiac autonomic
activity is important, as it implies we are able to intervene in this
harmful relationship. For instance, clinicians should take further
caution when prescribing certain classes of antidepressants,
especially TCAs and SNRIs, and more so when treating patients
with poor cardiovascular health.
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